Tags

Type your tag names separated by a space and hit enter

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cancer Gene Ther. 2004 Mar; 11(3):215-26.CG

Abstract

The activation of T cells plays a central role in antitumor immunity. In order to activate naïve T cells, two key signals are required. Signal one is provided through the T-cell receptor (TCR) while signal two is that of costimulation. The CD28:B7 molecules are one of the best-studied costimulatory pathways, thought to be the main mechanism through which primary T-cell stimulation occurs. However, a number of molecules have been identified which serve to amplify and diversify the T-cell response, following initial T-cell activation. These include the more recently described 4-1BB:4-1BB ligand (4-1BBL) molecules. 4-1BB:4-1BBL are a member of the TNFR:TNF ligand family, which are expressed on T cells and antigen-presenting cells (APCs), respectively. Therapies utilizing the 4-1BB:4-1BBL signaling pathway have been shown to have antitumor effects in a number of model systems. In this paper, we focus on the 4-1BB:4-1BBL costimulatory molecules. In particular, we will describe the structure and function of the 4-1BB molecule, its receptor and how 4-1BB:4-1BBL costimulation has and may be used for the immunotherapy of cancer.

Authors+Show Affiliations

Leukaemia Science Laboratories, Department of Haematological Medicine, Guy's, King's & St Thomas' School of Medicine, King's College London, Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

14671675

Citation

Cheuk, Adam T C., et al. "Role of 4-1BB:4-1BB Ligand in Cancer Immunotherapy." Cancer Gene Therapy, vol. 11, no. 3, 2004, pp. 215-26.
Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004;11(3):215-26.
Cheuk, A. T., Mufti, G. J., & Guinn, B. A. (2004). Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy, 11(3), 215-26.
Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB Ligand in Cancer Immunotherapy. Cancer Gene Ther. 2004;11(3):215-26. PubMed PMID: 14671675.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of 4-1BB:4-1BB ligand in cancer immunotherapy. AU - Cheuk,Adam T C, AU - Mufti,Ghulam J, AU - Guinn,Barbara-ann, PY - 2003/12/13/pubmed PY - 2004/9/29/medline PY - 2003/12/13/entrez SP - 215 EP - 26 JF - Cancer gene therapy JO - Cancer Gene Ther. VL - 11 IS - 3 N2 - The activation of T cells plays a central role in antitumor immunity. In order to activate naïve T cells, two key signals are required. Signal one is provided through the T-cell receptor (TCR) while signal two is that of costimulation. The CD28:B7 molecules are one of the best-studied costimulatory pathways, thought to be the main mechanism through which primary T-cell stimulation occurs. However, a number of molecules have been identified which serve to amplify and diversify the T-cell response, following initial T-cell activation. These include the more recently described 4-1BB:4-1BB ligand (4-1BBL) molecules. 4-1BB:4-1BBL are a member of the TNFR:TNF ligand family, which are expressed on T cells and antigen-presenting cells (APCs), respectively. Therapies utilizing the 4-1BB:4-1BBL signaling pathway have been shown to have antitumor effects in a number of model systems. In this paper, we focus on the 4-1BB:4-1BBL costimulatory molecules. In particular, we will describe the structure and function of the 4-1BB molecule, its receptor and how 4-1BB:4-1BBL costimulation has and may be used for the immunotherapy of cancer. SN - 0929-1903 UR - https://www.unboundmedicine.com/medline/citation/14671675/Role_of_4_1BB:4_1BB_ligand_in_cancer_immunotherapy_ L2 - http://dx.doi.org/10.1038/sj.cgt.7700670 DB - PRIME DP - Unbound Medicine ER -